Advaxis Inc
F:FAD2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Carl Zeiss Meditec AG
OTC:CZMWY
|
DE |
|
YCIC Eco Technology Co Ltd
SZSE:002200
|
CN |
|
R
|
Royal Century Resources Holdings Ltd
HKEX:8125
|
HK |
Advaxis Inc
Other Current Assets
Advaxis Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Advaxis Inc
F:FAD2
|
Other Current Assets
$2.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$6.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
$4B
|
CAGR 3-Years
31%
|
CAGR 5-Years
15%
|
CAGR 10-Years
6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$4.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$853.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
23%
|
CAGR 10-Years
21%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Assets
$1.2B
|
CAGR 3-Years
43%
|
CAGR 5-Years
50%
|
CAGR 10-Years
22%
|
|
Advaxis Inc
Glance View
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 15 full-time employees. The company went IPO on 2005-07-28. The Company’s products are based on a platform technology, which utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. The company is focused on single antigen and multiple antigen delivery products. The firm's pipeline of product candidates includes ADXS-503, which develops for treatment of non-small cell lung cancer; ADXS-504, which develops for the treatment of early-stage prostate cancer; and ADXS-PSA, which develops for the treatment of metastatic prostate cancer. Its ADXS-503 and ADXS-503 are in Phase I clinical trial. ADXS-PSA is in Phase II clinical trial. The company has completed and closed out clinical studies of Lm Technology immunotherapies in three program areas, HPV associated cancers, Personalized neoantigen-directed therapies and PSA directed therapy.
See Also
What is Advaxis Inc's Other Current Assets?
Other Current Assets
2.3m
USD
Based on the financial report for Dec 31, 2023, Advaxis Inc's Other Current Assets amounts to 2.3m USD.
What is Advaxis Inc's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
-16%
Over the last year, the Other Current Assets growth was -65%. The average annual Other Current Assets growth rates for Advaxis Inc have been -8% over the past three years , -16% over the past five years .
